|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1GALT1C1 |
Gene summary for C1GALT1C1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1GALT1C1 | Gene ID | 29071 |
| Gene name | C1GALT1 specific chaperone 1 | |
| Gene Alias | C1GALT2 | |
| Cytomap | Xq24 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q96EU7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29071 | C1GALT1C1 | LZE2T | Human | Esophagus | ESCC | 1.34e-02 | 5.85e-01 | 0.082 |
| 29071 | C1GALT1C1 | LZE4T | Human | Esophagus | ESCC | 1.32e-13 | 2.07e-01 | 0.0811 |
| 29071 | C1GALT1C1 | LZE7T | Human | Esophagus | ESCC | 1.99e-03 | 2.24e-01 | 0.0667 |
| 29071 | C1GALT1C1 | LZE8T | Human | Esophagus | ESCC | 9.13e-06 | 7.93e-02 | 0.067 |
| 29071 | C1GALT1C1 | LZE20T | Human | Esophagus | ESCC | 7.48e-03 | 1.71e-01 | 0.0662 |
| 29071 | C1GALT1C1 | LZE22T | Human | Esophagus | ESCC | 2.10e-05 | 2.79e-01 | 0.068 |
| 29071 | C1GALT1C1 | LZE24T | Human | Esophagus | ESCC | 3.96e-18 | 5.88e-01 | 0.0596 |
| 29071 | C1GALT1C1 | LZE21T | Human | Esophagus | ESCC | 2.18e-02 | 1.20e-01 | 0.0655 |
| 29071 | C1GALT1C1 | LZE6T | Human | Esophagus | ESCC | 2.92e-03 | 2.01e-01 | 0.0845 |
| 29071 | C1GALT1C1 | P1T-E | Human | Esophagus | ESCC | 4.19e-03 | 3.21e-01 | 0.0875 |
| 29071 | C1GALT1C1 | P2T-E | Human | Esophagus | ESCC | 2.88e-15 | 2.90e-01 | 0.1177 |
| 29071 | C1GALT1C1 | P4T-E | Human | Esophagus | ESCC | 1.13e-26 | 4.85e-01 | 0.1323 |
| 29071 | C1GALT1C1 | P5T-E | Human | Esophagus | ESCC | 1.64e-06 | 5.85e-02 | 0.1327 |
| 29071 | C1GALT1C1 | P8T-E | Human | Esophagus | ESCC | 8.77e-39 | 6.80e-01 | 0.0889 |
| 29071 | C1GALT1C1 | P9T-E | Human | Esophagus | ESCC | 3.25e-20 | 3.95e-01 | 0.1131 |
| 29071 | C1GALT1C1 | P10T-E | Human | Esophagus | ESCC | 3.94e-24 | 4.41e-01 | 0.116 |
| 29071 | C1GALT1C1 | P11T-E | Human | Esophagus | ESCC | 1.19e-12 | 5.09e-01 | 0.1426 |
| 29071 | C1GALT1C1 | P12T-E | Human | Esophagus | ESCC | 7.45e-20 | 1.57e-01 | 0.1122 |
| 29071 | C1GALT1C1 | P15T-E | Human | Esophagus | ESCC | 1.44e-20 | 1.63e-01 | 0.1149 |
| 29071 | C1GALT1C1 | P16T-E | Human | Esophagus | ESCC | 3.73e-14 | 1.81e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00064931 | Esophagus | ESCC | protein O-linked glycosylation | 51/8552 | 86/18723 | 7.54e-03 | 2.70e-02 | 51 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
| GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
| GO:007008511 | Oral cavity | LP | glycosylation | 77/4623 | 240/18723 | 5.60e-03 | 3.38e-02 | 77 |
| GO:000648611 | Oral cavity | LP | protein glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| GO:004341311 | Oral cavity | LP | macromolecule glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
| GO:00064866 | Thyroid | PTC | protein glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
| GO:00434136 | Thyroid | PTC | macromolecule glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C1GALT1C1 | SNV | Missense_Mutation | novel | c.162A>C | p.Lys54Asn | p.K54N | Q96EU7 | protein_coding | tolerated(0.46) | benign(0.013) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C1GALT1C1 | SNV | Missense_Mutation | c.771N>T | p.Glu257Asp | p.E257D | Q96EU7 | protein_coding | tolerated(0.32) | benign(0.042) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| C1GALT1C1 | SNV | Missense_Mutation | novel | c.652N>A | p.Ser218Thr | p.S218T | Q96EU7 | protein_coding | tolerated(0.07) | benign(0.39) | TCGA-HN-A2OB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
| C1GALT1C1 | SNV | Missense_Mutation | c.839N>T | p.Gly280Val | p.G280V | Q96EU7 | protein_coding | deleterious(0.04) | benign(0.297) | TCGA-EA-A439-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| C1GALT1C1 | SNV | Missense_Mutation | c.847C>T | p.Pro283Ser | p.P283S | Q96EU7 | protein_coding | tolerated(0.08) | benign(0.148) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1GALT1C1 | SNV | Missense_Mutation | c.64A>G | p.Ile22Val | p.I22V | Q96EU7 | protein_coding | tolerated(0.63) | benign(0) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| C1GALT1C1 | SNV | Missense_Mutation | c.366N>A | p.Met122Ile | p.M122I | Q96EU7 | protein_coding | tolerated(0.23) | benign(0.015) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1GALT1C1 | SNV | Missense_Mutation | novel | c.893N>T | p.Ala298Val | p.A298V | Q96EU7 | protein_coding | deleterious(0.05) | benign(0.017) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C1GALT1C1 | SNV | Missense_Mutation | c.305N>T | p.Ser102Phe | p.S102F | Q96EU7 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| C1GALT1C1 | SNV | Missense_Mutation | novel | c.521N>G | p.Lys174Arg | p.K174R | Q96EU7 | protein_coding | tolerated(0.1) | benign(0.052) | TCGA-AA-A00O-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |